How is increase in use of monoclonal Abs in cancer?

— Increase in numbers: (≃ 100 mAbs, all indications included) — Increase in indications : more cancer types — Increase in options: naked versus labeled — Better targeting : epitope refining — Protocols of cancer immunotherapy with mAb — In first line immunotherapy or for refractory tumors — Alone or in combination with chemotherapy or radiation therapy — As a complement to surgery for removal of subclinical microscopic tumors